NYRADA INC. - Announcements

7.41%

29.0¢

Market Cap $69.25M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

NYR	Preliminary Final Report	PRICE SENSITIVE	22/08/25	439.53KB	Share
NYR	Positive Final Review of Nyrada Phase I Clinical Trial	PRICE SENSITIVE	06/08/25	254.44KB	Share
NYR	Nyrada Successfully Raises $8.25 Million via Placement	PRICE SENSITIVE	04/08/25	309.41KB	Share
NYR	Trading Halt	PRICE SENSITIVE	31/07/25	336.99KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/07/25	451.07KB	Share
NYR	NYR Advances Xolatryp Phase IIa Trial in Cardioprotection	PRICE SENSITIVE	23/07/25	287.44KB	Share
NYR	Final Phase I Clinical Trial Patients Dosed and Discharged	PRICE SENSITIVE	21/07/25	284.22KB	Share
NYR	Final Nyrada Phase I Clinical Trial Cohort to Commence	PRICE SENSITIVE	14/07/25	282.83KB	Share
NYR	Phase I Clinical Trial Dosing Update No 4	PRICE SENSITIVE	16/06/25	267.76KB	Share
NYR	Phase I Clinical Trial Protocol Amendment	PRICE SENSITIVE	04/06/25	260.08KB	Share
NYR	Phase I Clinical Trial Dosing Update No 3	PRICE SENSITIVE	21/05/25	245.1KB	Share
NYR	NOX: New funds from Nyrada share sales	PRICE SENSITIVE	20/05/25	193.35KB	Share
NYR	NYR-BI03 Extends Cardioprotection to Arrhythmia Control	PRICE SENSITIVE	08/05/25	332.15KB	Share
NYR	Phase I Clinical Trial Dosing Update No 2	PRICE SENSITIVE	02/05/25	224.62KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	15/04/25	487.88KB	Share
NYR	Phase I Clinical Trial Dosing Update No 1	PRICE SENSITIVE	09/04/25	301.12KB	Share
NYR	Significant Neuroprotection in Traumatic Brain Injury Study	PRICE SENSITIVE	07/04/25	340.77KB	Share
NYR	First Cohort Dosed in Nyradas Phase I Clinical Trial	PRICE SENSITIVE	31/03/25	229.29KB	Share
NYR	Appendix 4D and Half Year Report to 31 December 2024	PRICE SENSITIVE	18/02/25	458.23KB	Share
NYR	Nyrada to Commence Phase Ia Clinical Trial	PRICE SENSITIVE	07/02/25	233.68KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	23/01/25	461.69KB	Share
NYR	Nyrada Successfully Raises $3.36 Million via Placement	PRICE SENSITIVE	28/10/24	251.07KB	Share
NYR	Trading Halt	PRICE SENSITIVE	24/10/24	613.42KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	24/10/24	455.24KB	Share
NYR	Supplementary NYR-BI03 Study Confirm Strong Cardioprotection	PRICE SENSITIVE	23/10/24	312.38KB	Share
NYR	NYR Completes Safety Studies Ahead of Phase I Clinical Trial	PRICE SENSITIVE	16/10/24	294.23KB	Share
NYR	Brain Injury Program GLP Studies Further Update 6	PRICE SENSITIVE	07/10/24	252.33KB	Share
NYR	Drug Candidate Demonstrates Significant Cardioprotection	PRICE SENSITIVE	01/10/24	290.47KB	Share
NYR	Trading Halt	PRICE SENSITIVE	01/10/24	600.3KB	Share
NYR	Pause in Trading	PRICE SENSITIVE	01/10/24	111.95KB	Share
NYR	Brain Injury Program GLP Studies Further Update 5	PRICE SENSITIVE	27/09/24	264.95KB	Share
NYR	Brain Injury Program GLP Studies Further Update 4	PRICE SENSITIVE	09/09/24	282.76KB	Share
NYR	Preliminary final report	PRICE SENSITIVE	22/08/24	159.66KB	Share
NYR	Brain Injury Program GLP Studies Further Update No 3	PRICE SENSITIVE	20/08/24	282.6KB	Share
NYR	Brain Injury Program GLP Studies Further Update	PRICE SENSITIVE	06/08/24	255.31KB	Share
NYR	GLP Studies Update	PRICE SENSITIVE	16/07/24	232KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	09/07/24	433.42KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	10/04/24	978.77KB	Share
NYR	Nyrada Successfully Raises $1.755 Million via Placement	PRICE SENSITIVE	06/03/24	269.15KB	Share
NYR	Trading Halt	PRICE SENSITIVE	04/03/24	271.13KB	Share
NYR	Significant Neuroprotection in NYR Preclinical Brain Injury	PRICE SENSITIVE	28/02/24	361.76KB	Share
NYR	Appendix 4D and Half Year Report to 31 December 2023	PRICE SENSITIVE	20/02/24	901.25KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	17/01/24	410.56KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	13/10/23	437.58KB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	28/08/23	390.58KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/07/23	403.65KB	Share
NYR	Cholesterol-Lowering Program Update	PRICE SENSITIVE	26/06/23	217.19KB	Share
NYR	Brain Injury Program Preclinical Development Update	PRICE SENSITIVE	09/06/23	254.07KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/04/23	431.69KB	Share
NYR	Cholesterol-Lowering Program Preclinical Development Update	PRICE SENSITIVE	11/04/23	218.53KB	Share
NYR	Appendix 4D and Half Year Report to 31 December 2022	PRICE SENSITIVE	24/02/23	774.49KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/01/23	436.49KB	Share
NYR	Collaboration with Walter Reed and UNSW Extended to 2025	PRICE SENSITIVE	18/01/23	304.95KB	Share
NYR	Brain Injury Program Update	PRICE SENSITIVE	11/01/23	234.88KB	Share
NYR	Nyrada Receives A$1.2M R&D Tax Incentive Rebate	PRICE SENSITIVE	18/11/22	217.81KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/10/22	554.93KB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	29/08/22	205.27KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/07/22	434.69KB	Share
NYR	Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis	PRICE SENSITIVE	20/07/22	207.35KB	Share
NYR	Cholesterol-Lowering Program Update	PRICE SENSITIVE	29/06/22	215.89KB	Share
NYR	Corporate Presentation	PRICE SENSITIVE	07/06/22	1.82MB	Share
NYR	Brain Injury Program Target Unveiled and Phase I Update	PRICE SENSITIVE	06/06/22	310.7KB	Share
NYR	European Patent to be Granted for Cholesterol-Lowering Drug	PRICE SENSITIVE	17/05/22	223.96KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	19/04/22	422.49KB	Share
NYR	New Drug Offers Potential Oral Treatment for Concussion	PRICE SENSITIVE	29/03/22	301.04KB	Share
NYR	Nyrada Half Year Results FY2022	PRICE SENSITIVE	25/02/22	283.42KB	Share
NYR	Appendix 4D and Half Year Report to 31 December 2021	PRICE SENSITIVE	25/02/22	573.91KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	21/01/22	579.1KB	Share
NYR	Nyrada Receives A$1.3M R&D Tax Incentive Rebate	PRICE SENSITIVE	12/01/22	218.39KB	Share
NYR	Cholesterol-Lowering Program Pathway to Phase I	PRICE SENSITIVE	22/12/21	201.38KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	26/10/21	488.88KB	Share
NYR	Nyrada Reports Full Year FY2021 Results	PRICE SENSITIVE	30/08/21	254.9KB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	30/08/21	226.37KB	Share
NYR	Nyrada Announces US Patent Grant for PCSK9 Inhibitor	PRICE SENSITIVE	30/07/21	224.97KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	27/07/21	545.06KB	Share
NYR	NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction	PRICE SENSITIVE	29/06/21	405.5KB	Share
NYR	Improved Drug Candidate Selected for WRAIR Studies	PRICE SENSITIVE	15/06/21	290.19KB	Share
NYR	Nyrada Receives A$1.0M R&D Tax Incentive Rebate	PRICE SENSITIVE	06/05/21	191.19KB	Share
NYR	NYR Announces New Potent Cholesterol-Lowering Candidates	PRICE SENSITIVE	05/05/21	320.6KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	20/04/21	514.32KB	Share
NYR	Nyrada Receives Firm Commitments to Raise A$11 Million	PRICE SENSITIVE	22/03/21	231.78KB	Share
NYR	Trading Halt	PRICE SENSITIVE	17/03/21	236.75KB	Share
NYR	Nyrada Reports Half Year FY2021 Results	PRICE SENSITIVE	22/02/21	239.67KB	Share
NYR	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	22/02/21	700.02KB	Share
NYR	NYR Secures Collaboration with Walter Reed and UNSW	PRICE SENSITIVE	01/02/21	326.73KB	Share
NYR	Trading Halt	PRICE SENSITIVE	29/01/21	251.74KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	28/01/21	543.49KB	Share
NYR	57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study	PRICE SENSITIVE	21/12/20	307.97KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	13/10/20	460.69KB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	31/08/20	388.18KB	Share
NYR	Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure	PRICE SENSITIVE	29/07/20	206KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	22/07/20	331.58KB	Share
NYR	Nyrada Brain Injury Drug Pharmacokinetic Study Results	PRICE SENSITIVE	15/07/20	259.66KB	Share
NYR	Nyrada Cholesterol-Lowering Drug Study Results	PRICE SENSITIVE	06/07/20	230.95KB	Share
NYR	Milestone Achieved in the Nyrada Brain Injury Program	PRICE SENSITIVE	25/05/20	227.68KB	Share
NYR	Appendix 4C - March 2020 quarterly	PRICE SENSITIVE	14/04/20	1.17MB	Share
NYR	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	25/02/20	943.38KB	Share

NYR Preliminary Final Report
22/08/25	PRICE SENSITIVE	439.53KB	Share
NYR Positive Final Review of Nyrada Phase I Clinical Trial
06/08/25	PRICE SENSITIVE	254.44KB	Share
NYR Nyrada Successfully Raises $8.25 Million via Placement
04/08/25	PRICE SENSITIVE	309.41KB	Share
NYR Trading Halt
31/07/25	PRICE SENSITIVE	336.99KB	Share
NYR Quarterly Activities Report and Appendix 4C
31/07/25	PRICE SENSITIVE	451.07KB	Share
NYR NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
23/07/25	PRICE SENSITIVE	287.44KB	Share
NYR Final Phase I Clinical Trial Patients Dosed and Discharged
21/07/25	PRICE SENSITIVE	284.22KB	Share
NYR Final Nyrada Phase I Clinical Trial Cohort to Commence
14/07/25	PRICE SENSITIVE	282.83KB	Share
NYR Phase I Clinical Trial Dosing Update No 4
16/06/25	PRICE SENSITIVE	267.76KB	Share
NYR Phase I Clinical Trial Protocol Amendment
04/06/25	PRICE SENSITIVE	260.08KB	Share
NYR Phase I Clinical Trial Dosing Update No 3
21/05/25	PRICE SENSITIVE	245.1KB	Share
NYR NOX: New funds from Nyrada share sales
20/05/25	PRICE SENSITIVE	193.35KB	Share
NYR NYR-BI03 Extends Cardioprotection to Arrhythmia Control
08/05/25	PRICE SENSITIVE	332.15KB	Share
NYR Phase I Clinical Trial Dosing Update No 2
02/05/25	PRICE SENSITIVE	224.62KB	Share
NYR Quarterly Activities Report and Appendix 4C
15/04/25	PRICE SENSITIVE	487.88KB	Share
NYR Phase I Clinical Trial Dosing Update No 1
09/04/25	PRICE SENSITIVE	301.12KB	Share
NYR Significant Neuroprotection in Traumatic Brain Injury Study
07/04/25	PRICE SENSITIVE	340.77KB	Share
NYR First Cohort Dosed in Nyradas Phase I Clinical Trial
31/03/25	PRICE SENSITIVE	229.29KB	Share
NYR Appendix 4D and Half Year Report to 31 December 2024
18/02/25	PRICE SENSITIVE	458.23KB	Share
NYR Nyrada to Commence Phase Ia Clinical Trial
07/02/25	PRICE SENSITIVE	233.68KB	Share
NYR Quarterly Activities Report and Appendix 4C
23/01/25	PRICE SENSITIVE	461.69KB	Share
NYR Nyrada Successfully Raises $3.36 Million via Placement
28/10/24	PRICE SENSITIVE	251.07KB	Share
NYR Trading Halt
24/10/24	PRICE SENSITIVE	613.42KB	Share
NYR Quarterly Activities Report and Appendix 4C
24/10/24	PRICE SENSITIVE	455.24KB	Share
NYR Supplementary NYR-BI03 Study Confirm Strong Cardioprotection
23/10/24	PRICE SENSITIVE	312.38KB	Share
NYR NYR Completes Safety Studies Ahead of Phase I Clinical Trial
16/10/24	PRICE SENSITIVE	294.23KB	Share
NYR Brain Injury Program GLP Studies Further Update 6
07/10/24	PRICE SENSITIVE	252.33KB	Share
NYR Drug Candidate Demonstrates Significant Cardioprotection
01/10/24	PRICE SENSITIVE	290.47KB	Share
NYR Trading Halt
01/10/24	PRICE SENSITIVE	600.3KB	Share
NYR Pause in Trading
01/10/24	PRICE SENSITIVE	111.95KB	Share
NYR Brain Injury Program GLP Studies Further Update 5
27/09/24	PRICE SENSITIVE	264.95KB	Share
NYR Brain Injury Program GLP Studies Further Update 4
09/09/24	PRICE SENSITIVE	282.76KB	Share
NYR Preliminary final report
22/08/24	PRICE SENSITIVE	159.66KB	Share
NYR Brain Injury Program GLP Studies Further Update No 3
20/08/24	PRICE SENSITIVE	282.6KB	Share
NYR Brain Injury Program GLP Studies Further Update
06/08/24	PRICE SENSITIVE	255.31KB	Share
NYR GLP Studies Update
16/07/24	PRICE SENSITIVE	232KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
09/07/24	PRICE SENSITIVE	433.42KB	Share
NYR Quarterly Activities Report and Appendix 4C
10/04/24	PRICE SENSITIVE	978.77KB	Share
NYR Nyrada Successfully Raises $1.755 Million via Placement
06/03/24	PRICE SENSITIVE	269.15KB	Share
NYR Trading Halt
04/03/24	PRICE SENSITIVE	271.13KB	Share
NYR Significant Neuroprotection in NYR Preclinical Brain Injury
28/02/24	PRICE SENSITIVE	361.76KB	Share
NYR Appendix 4D and Half Year Report to 31 December 2023
20/02/24	PRICE SENSITIVE	901.25KB	Share
NYR Quarterly Activities Report and Appendix 4C
17/01/24	PRICE SENSITIVE	410.56KB	Share
NYR Quarterly Activities Report and Appendix 4C
13/10/23	PRICE SENSITIVE	437.58KB	Share
NYR Preliminary Final Report
28/08/23	PRICE SENSITIVE	390.58KB	Share
NYR Quarterly Activities Report and Appendix 4C
28/07/23	PRICE SENSITIVE	403.65KB	Share
NYR Cholesterol-Lowering Program Update
26/06/23	PRICE SENSITIVE	217.19KB	Share
NYR Brain Injury Program Preclinical Development Update
09/06/23	PRICE SENSITIVE	254.07KB	Share
NYR Quarterly Activities Report and Appendix 4C
26/04/23	PRICE SENSITIVE	431.69KB	Share
NYR Cholesterol-Lowering Program Preclinical Development Update
11/04/23	PRICE SENSITIVE	218.53KB	Share
NYR Appendix 4D and Half Year Report to 31 December 2022
24/02/23	PRICE SENSITIVE	774.49KB	Share
NYR Quarterly Activities Report and Appendix 4C
30/01/23	PRICE SENSITIVE	436.49KB	Share
NYR Collaboration with Walter Reed and UNSW Extended to 2025
18/01/23	PRICE SENSITIVE	304.95KB	Share
NYR Brain Injury Program Update
11/01/23	PRICE SENSITIVE	234.88KB	Share
NYR Nyrada Receives A$1.2M R&D Tax Incentive Rebate
18/11/22	PRICE SENSITIVE	217.81KB	Share
NYR Quarterly Activities Report and Appendix 4C
26/10/22	PRICE SENSITIVE	554.93KB	Share
NYR Preliminary Final Report
29/08/22	PRICE SENSITIVE	205.27KB	Share
NYR Quarterly Activities Report and Appendix 4C
26/07/22	PRICE SENSITIVE	434.69KB	Share
NYR Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
20/07/22	PRICE SENSITIVE	207.35KB	Share
NYR Cholesterol-Lowering Program Update
29/06/22	PRICE SENSITIVE	215.89KB	Share
NYR Corporate Presentation
07/06/22	PRICE SENSITIVE	1.82MB	Share
NYR Brain Injury Program Target Unveiled and Phase I Update
06/06/22	PRICE SENSITIVE	310.7KB	Share
NYR European Patent to be Granted for Cholesterol-Lowering Drug
17/05/22	PRICE SENSITIVE	223.96KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
19/04/22	PRICE SENSITIVE	422.49KB	Share
NYR New Drug Offers Potential Oral Treatment for Concussion
29/03/22	PRICE SENSITIVE	301.04KB	Share
NYR Nyrada Half Year Results FY2022
25/02/22	PRICE SENSITIVE	283.42KB	Share
NYR Appendix 4D and Half Year Report to 31 December 2021
25/02/22	PRICE SENSITIVE	573.91KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
21/01/22	PRICE SENSITIVE	579.1KB	Share
NYR Nyrada Receives A$1.3M R&D Tax Incentive Rebate
12/01/22	PRICE SENSITIVE	218.39KB	Share
NYR Cholesterol-Lowering Program Pathway to Phase I
22/12/21	PRICE SENSITIVE	201.38KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
26/10/21	PRICE SENSITIVE	488.88KB	Share
NYR Nyrada Reports Full Year FY2021 Results
30/08/21	PRICE SENSITIVE	254.9KB	Share
NYR Preliminary Final Report
30/08/21	PRICE SENSITIVE	226.37KB	Share
NYR Nyrada Announces US Patent Grant for PCSK9 Inhibitor
30/07/21	PRICE SENSITIVE	224.97KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
27/07/21	PRICE SENSITIVE	545.06KB	Share
NYR NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction
29/06/21	PRICE SENSITIVE	405.5KB	Share
NYR Improved Drug Candidate Selected for WRAIR Studies
15/06/21	PRICE SENSITIVE	290.19KB	Share
NYR Nyrada Receives A$1.0M R&D Tax Incentive Rebate
06/05/21	PRICE SENSITIVE	191.19KB	Share
NYR NYR Announces New Potent Cholesterol-Lowering Candidates
05/05/21	PRICE SENSITIVE	320.6KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
20/04/21	PRICE SENSITIVE	514.32KB	Share
NYR Nyrada Receives Firm Commitments to Raise A$11 Million
22/03/21	PRICE SENSITIVE	231.78KB	Share
NYR Trading Halt
17/03/21	PRICE SENSITIVE	236.75KB	Share
NYR Nyrada Reports Half Year FY2021 Results
22/02/21	PRICE SENSITIVE	239.67KB	Share
NYR Appendix 4D and Half Year Accounts
22/02/21	PRICE SENSITIVE	700.02KB	Share
NYR NYR Secures Collaboration with Walter Reed and UNSW
01/02/21	PRICE SENSITIVE	326.73KB	Share
NYR Trading Halt
29/01/21	PRICE SENSITIVE	251.74KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
28/01/21	PRICE SENSITIVE	543.49KB	Share
NYR 57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study
21/12/20	PRICE SENSITIVE	307.97KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
13/10/20	PRICE SENSITIVE	460.69KB	Share
NYR Preliminary Final Report
31/08/20	PRICE SENSITIVE	388.18KB	Share
NYR Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure
29/07/20	PRICE SENSITIVE	206KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
22/07/20	PRICE SENSITIVE	331.58KB	Share
NYR Nyrada Brain Injury Drug Pharmacokinetic Study Results
15/07/20	PRICE SENSITIVE	259.66KB	Share
NYR Nyrada Cholesterol-Lowering Drug Study Results
06/07/20	PRICE SENSITIVE	230.95KB	Share
NYR Milestone Achieved in the Nyrada Brain Injury Program
25/05/20	PRICE SENSITIVE	227.68KB	Share
NYR Appendix 4C - March 2020 quarterly
14/04/20	PRICE SENSITIVE	1.17MB	Share
NYR Appendix 4D and Half Year Accounts
25/02/20	PRICE SENSITIVE	943.38KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 29.0¢		Change 0.020(7.41%)		Mkt cap ! $69.25M

Open	High	Low	Value	Volume
27.0¢	29.0¢	27.0¢	$125.1K	445.1K

Buyers (Bids)

No.	Vol.	Price($)
2	19172	29.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.5¢	7200	1

View Market Depth

No.	Vol.	Price($)
1	2000	0.290
2	15000	0.285
2	32000	0.280
1	36363	0.275
1	67735	0.270

Price($)	Vol.	No.
0.295	7200	1
0.300	20000	1
0.310	15075	2
0.320	178150	4
0.340	69332	1

Last trade - 16.10pm 05/09/2025 (20 minute delay)

NYR (ASX) Chart

NYRADA INC. - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories